Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.077 AUD | 0.00% | +2.67% | -3.75% |
Mar. 27 | Amplia Concludes Phase I Trials of Anti-Cancer Drug; Prepares for Phase II | MT |
Mar. 27 | Amplia Therapeutics Updates on Pancreatic Cancer Trial; Phase-Two Recruitment Ongoing; Shares Up 3% | MT |
Sales 2022 | 1.98M 1.29M | Sales 2023 | 1.19M 775K | Capitalization | 16.49M 10.75M |
---|---|---|---|---|---|
Net income 2022 | -3M -1.96M | Net income 2023 | -6M -3.91M | EV / Sales 2022 | 7.87 x |
Net cash position 2022 | 12.51M 8.15M | Net cash position 2023 | 6.98M 4.55M | EV / Sales 2023 | 7.99 x |
P/E ratio 2022 |
-5.79
x | P/E ratio 2023 |
-2.64
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 78.92% |
1 week | +2.67% | ||
Current month | +2.67% | ||
1 month | -3.75% | ||
3 months | -3.75% | ||
6 months | -2.53% | ||
Current year | -3.75% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 00-05-30 | |
Tim Luscombe
DFI | Director of Finance/CFO | - | 23-09-24 |
Rhiannon Jones
COO | Chief Operating Officer | - | 21-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Cooke
SEC | Corporate Secretary | 62 | 13-10-10 |
Robert Peach
BRD | Director/Board Member | 68 | 15-09-01 |
Warwick Tong
CHM | Chairman | - | 18-05-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 0.077 | 0.00% | 201 547 |
24-03-27 | 0.077 | +2.67% | 126,117 |
24-03-26 | 0.075 | -2.60% | 49,177 |
24-03-25 | 0.077 | 0.00% | 51,862 |
24-03-22 | 0.077 | 0.00% | 39,358 |
Delayed Quote Australian S.E., March 28, 2024 at 12:57 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-3.75% | 9.75M | |
+2.61% | 108B | |
+9.72% | 104B | |
+6.58% | 23.66B | |
-12.34% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.02% | 16.19B | |
+4.22% | 13.72B | |
+33.78% | 12.22B |